

11th September, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Successful completion of unannounced USFDA onsite inspection at Alembic Pharmaceuticals Limited's Bioequivalence Facility in Vadodara, Gujarat

We are pleased to inform the stock exchanges that Alembic Pharmaceuticals Limited ('Company'), has successfully completed an unannounced onsite Bioequivalence inspection conducted by United States Food and Drug Administration ('USFDA') at the Company's Bioequivalence Facility located in Vadodara, Gujarat, with no Form 483 observations.

The unannounced onsite USFDA Bioequivalence inspection was conducted from 31st August, 2026 to 10th September, 2026.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Chirag K. Shukla
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123